2026 Strategy
Building on 2025's business model validation and 145% invoiced growth, 2026 focuses on specialized scaling through segment expertise and geographic expansion.
Revenue Target: €1.3M
| Metric | Target | Baseline (2025) | Growth |
|---|---|---|---|
| Revenue | €1.3M | €604,495 | 2.15x |
Revenue Buildup
The €1.3M target is built on four layers of increasing certainty:
| Layer | Amount | Cumulative | Source | Confidence |
|---|---|---|---|---|
| 1. Signed contracts | €316K | €316K | Fixed-amount contracts (J&J, BI, IMQ) | High |
| 2. Current clients | €631K | €631K | Layer 1 + consumption-based renewals | Medium-High |
| 3. Pipeline conversion | €966K | €966K | Layer 2 + pipeline at HubSpot success rates | Medium |
| 4. New business | €334K | €1.3M | New clients + pipeline outperformance | Target |
Breakdown by segment:
| Layer | Clinical Practice | Clinical Research | Total |
|---|---|---|---|
| Signed contracts | €89K | €227K | €316K |
| Current clients | €404K | €227K | €631K |
| Pipeline conversion | €554K | €412K | €966K |
Revenue by Deal
The €966K pipeline target is built on 43 identified deals from the CRM. Amounts represent forecasted revenue (TCV weighted by close probability per HubSpot pipeline stage), not total contract values:
| Deal | 2026 (€) |
|---|---|
| US Pharma J&J Clinical Trial Psoriasis Phase 3 | 208,392 |
| US J&J Retrospective Analysis (AD & Pso) | 106,242 |
| ES Teladoc Health for Adeslas Pilot | 84,000 |
| ES SESPA Licitacion Telefonica | 79,150 |
| ES Sanitas Renewal del Grupo | 72,675 |
| ES Generalitat Valenciana Licitacion | 63,924 |
| ES Boehringer Ingelheim Sponsor the App | 55,980 |
| SE Visiba Care Chatbot Triage | 30,000 |
| EU ICON & Almirall AD Phase 3 Study | 26,604 |
| Quantificare & Sanofi AD Clinical Trials (5 Studies) | 25,281 |
| BR J&J Oncoderm RWE Study Pilot | 19,362 |
| US J&J Psoriasis Support Patient App | 18,720 |
| ES Hospital Universitario de Torrejon | 18,000 |
| FR Pierre Fabre Eczema Foundation License (Part 2) | 17,065 |
| FR AbbVie Calculators | 16,000 |
| DK Trifork Remote Wounds Monitoring | 14,000 |
| ES Telefonica IB Salut | 13,430 |
| PL Lux Med Bupa | 11,565 |
| Quantificare Alopecia Clinical Trial | 10,502 |
| UK Glenmark RWE Acne Clinical Trial | 10,318 |
| ES IMQ Insurance GP Support | 8,100 |
| ES Almirall Retrospective Study HS | 7,800 |
| Quantificare & Takeda AD Clinical Trial | 6,599 |
| Pfizer SALT Calculator | 5,560 |
| HK Eli Lilly SALT Calculator | 5,172 |
| CZ Novartis HS Care Providers | 5,105 |
| US Sagimet Phase 2 Alopecia Clinical Trial | 5,000 |
| US ICON & Protagonist Phase 2 Psoriasis | 4,379 |
| PL Lux Med Pilot | 3,283 |
| ES Orion Health | 1,848 |
| CL Bupa Group Triaje y Derivaciones | 1,599 |
| ES IGDerma Apoyo Diagnostico y Follow-up | 1,512 |
| ES Telefonica Aragon | 1,318 |
| ES Cigna Renovacion 2026 | 1,080 |
| ES Quironsalud Digital Pilot | 1,057 |
| NL CRO CHDR Retrospective Study | 1,000 |
| PT CUF Hospitais | 958 |
| FR ADDAX Podologist Use Case | 900 |
| ES Sanitas Chequeos Digitales (BluaU) | 723 |
| IE Pfizer | 600 |
| DE GoMedicus Group | 600 |
| UK Cigna Patients App Implementation | 600 |
| IE Irish Life Health | 533 |
| Total | 966,535 |
Key Assumptions
- Signed contracts recognize on schedule (€316K baseline)
- Current clients renew at 90%+ retention (2025: 92% top-half, 83% bottom-half)
- Pipeline converts at historical rates per HubSpot stage probabilities
- New business fills the €334K gap through prospecting and pipeline outperformance
Strategic Pillars
1. Scale Insurance
Focus: Grow revenue from existing insurance clients across current markets
Key drivers:
- Sanitas renewal (TCV €230K over 3 years, ~€76K ACV)
- IMQ expansion from initial deployment
- Lux Med (Poland) scaling post-pilot
2. New Markets
Priority #1: Brazil
- Critical specialist shortage (1 dermatologist per 100,000 people)
- Massive private insurance market
- Anchors: J&J Oncoderm RWE Study active, Novartis
Priority #2: United Kingdom
- High need (NHS pressure on dermatology waiting lists)
- UKCA certification already obtained; NHS-specific certifications still in progress
- Need to build a solid ROI model for NHS adoption (public sector requires additional compliance; private sector is a separate, faster track)
- Strategic urgency: an established local competitor already holds strong NHS positioning, making early market entry critical to secure share before the space consolidates around a single provider
3. Consolidate Public Sector
Focus: Spain
Target regions:
- Valencia (Generalitat Valenciana)
- Aragon (Telefonica partnership)
- Asturias (SESPA expansion)
4. Partner for Clinical Trials
Strategy: Indirect sales via CROs & Quantificare partnership
Anchor client: Johnson & Johnson (€434K active contract)
5. Prepare US Market Entry
Focus: Building foundations for commercial launch post-FDA clearance
Key actions:
- FDA 510(k) process underway, regulatory preparation ongoing
- Clinical Research as beachhead: leveraging active pharma partnerships (J&J, Pfizer, Sagimet) to build US clinical evidence and brand recognition before commercial launch
- Market development: establishing contacts with potential US partners, insurers, and health systems so the company is ready to sell as soon as FDA clearance is obtained
Dual Engine Approach
Engine 1: Clinical Practice (Volume)
| Attribute | Details |
|---|---|
| Target | Insurers, Public Health, Telemedicine |
| Value Prop | Triage efficiency, claims optimization, waiting list reduction |
| Deal Size | €10K-€200K |
Engine 2: Clinical Research (Value)
| Attribute | Details |
|---|---|
| Target | Pharma & CROs |
| Value Prop | Objective severity scoring, Real-World Evidence (RWE) |
| Deal Size | €50K-€500K per study |
Pipeline Status
| Metric | Value |
|---|---|
| Total pipeline | €3.9M |
| Opportunities in prospection | 56 |
| Qualified opportunities | 36 |
| Approved offers | €100K |
Geographic Priorities
| Region | Priority | Focus |
|---|---|---|
| Spain | Consolidate | Public Sector & Insurance |
| Brazil | #1 New Entry | Insurance |
| UK | #2 New Entry | NHS |
| US | Prepare Entry | Clinical Research & FDA process |
Risk Factors
- Long sales cycles in healthcare (6-18 months)
- Product readiness: Life Science features are not fully mature yet, which poses a delivery risk for Clinical Research deals; Clinical Practice product is stable
- Clinical trials dependency on Quantificare partnership ramp-up
- New market entry requires local regulatory compliance